Details for Patent: 11,918,557
✉ Email this page to a colleague
Which drugs does patent 11,918,557 protect, and when does it expire?
Patent 11,918,557 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has one hundred and forty-seven patent family members in twenty-three countries.
Recent additions to Drugs Protected by US Patent 11,918,557
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE | 205677 | Jan 31, 2014 | RX | Yes | ⤷ Subscribe | ⤷ Subscribe | U-3003 | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE | 205677 | Jan 31, 2014 | RX | Yes | ⤷ Subscribe | ⤷ Subscribe | U-3865 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION | 214517 | Dec 1, 2020 | RX | Yes | ⤷ Subscribe | ⤷ Subscribe | U-3003 | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,918,557
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Subscribe | |||
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON | ⤷ Subscribe | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,918,557
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013211878 | ⤷ Subscribe | |||
| Australia | 2013211880 | ⤷ Subscribe | |||
| Australia | 2013361459 | ⤷ Subscribe | |||
| Australia | 2015206797 | ⤷ Subscribe | |||
| Australia | 2016204178 | ⤷ Subscribe | |||
| Australia | 2016204217 | ⤷ Subscribe | |||
| Australia | 2018201302 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
